Analysts at B. Riley issued their Q1 2025 EPS estimates for LifeMD in a research report issued to clients and investors on Tuesday, March 11th. B. Riley analyst A. Schock anticipates that the company ...
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good afternoon. Thank you for joining us to discuss LifeMD, Inc.
LifeMD Inc (LFMD) reports a 43% revenue increase and unveils plans for new product launches and Medicare offerings amid ...
Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, ...
H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The ...
Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...
In a report released on March 11, Steven Valiquette from Mizuho Securities maintained a Hold rating on LifeMD (LFMD – Research Report). The ...
As the U.S. stock market grapples with political and economic uncertainty, leading to a correction in major indices like the S&P 500 and Nasdaq Composite, investors are increasingly seeking stability ...
Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug ...
LifeMD reported a fourth-quarter loss per share of 2 cents. Analysts were expecting a loss of 5 cents per share, according to FactSet. Revenue for the fourth quarter came in at $64.3 million. Analysts ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results